Class summary at a glance.

Every drug in the Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 11tracked in Part D
CY24 Part D spend: $7.5Mcombined across class
Total Rx claims: 35K6K unique beneficiaries
Generic mfrs (active): 24across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Abacavir

Brand: Abacavir · 23K Part D claims (CY24) · 4K beneficiaries · First FDA approval: 1999-01-28

5 generic mfrs 0 plans require PA

Low NADAC$0.652

→

Avg plan cost$0.652

Part D spend $4.2M 1× spread, current vs floor

Class share

56%

of class CY24 spend

View profile →

Emtricitabine

Brand: Emtriva · 8K Part D claims (CY24) · 2K beneficiaries · First FDA approval: 2003-07-02

2 generic mfrs 0 plans require PA

Low NADAC$14.51

→

Avg plan cost$15.49

Part D spend $3.0M 1× spread, current vs floor

Class share

41%

of class CY24 spend

View profile →

Zidovudine

Brand: RETROVIR · 4K Part D claims (CY24) · 706 beneficiaries · First FDA approval: 2005-09-19

4 generic mfrs 0 plans require PA

Low NADAC$0.150

→

Avg plan cost$0.291

Part D spend $250683 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Bictegravir Sodium, Emtricitabine, and Tenofovir Alafenamide

Brand: Biktarvy · — Part D claims (CY24) · First FDA approval: 2018-02-07

Brand-only (no generics) 0 plans require PA

Low NADAC$136.73

→

Avg plan cost$136.74

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Emtricitabine and Tdf

— Part D claims (CY24) · First FDA approval: 2022-12-05

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Emtricitabine and Tenofovir Alafenamide

Brand: DESCOVY · — Part D claims (CY24) · First FDA approval: 2016-04-04

1 generic mfrs 0 plans require PA

Low NADAC$71.41

→

Avg plan cost$71.43

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Emtricitabine and Tenofovir Disoproxil

Brand: Truvada · — Part D claims (CY24) · First FDA approval: 2004-08-02

10 generic mfrs 0 plans require PA

Low NADAC$0.457

→

Avg plan cost$5.37

Part D spend — 12× spread, current vs floor

Class share

of class CY24 spend

View profile →

Emtricitabine, Rilpivirine Hydrochloride, and Tenofovir Alafenamide

Brand: ODEFSEY · — Part D claims (CY24) · First FDA approval: 2016-03-01

Brand-only (no generics) 0 plans require PA

Low NADAC$130.35

→

Avg plan cost$130.35

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Emtricitabine, Rilpivirine Hydrochloride, and Tenofovir Disoproxil

Brand: COMPLERA · — Part D claims (CY24) · First FDA approval: 2011-08-10

Brand-only (no generics) 0 plans require PA

Low NADAC$130.52

→

Avg plan cost$130.52

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Emtricitabine, Rilpivirine and Tenofovir Disoproxil

— Part D claims (CY24) · First FDA approval: 2026-03-05

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Emtricitabine, Rilpivirine, Tenofovir Disoproxil

— Part D claims (CY24) · First FDA approval: 2025-05-27

2 generic mfrs 0 plans require PA

Low NADAC$114.86

→

Avg plan cost$114.86

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.